SAN CARLOS, Calif.–(–)–Q Bio, a quantitative, clinically-relevant assessment of personal human health, today announced it has officially come out of stealth mode and secured $40 million in Series B funding led by Andreessen Horowitz. This brings Q Bio’s total funding to $58 million. This latest round of funding will allow Q Bio to continue to improve its proprietary platform and technology to make their preventive health services faster, better and more affordable for all.
“Since my own misdiagnoses over a decade ago, I’ve imagined a day when everything about a person’s body could be quickly measured, shared and analyzed. It took time but Q Bio was born,” said Jeffrey Kaditz, co-founder and CEO of Q Bio. “We are thrilled to have our current investors continue to share our vision and excitement for what is possible in the field of preventive health.”
With a mission to empower people with a deeper understanding of their body and how it’s changing, so they have more control over their health, Q Bio was founded in late 2015. The company has spent the last few years in stealth mode, focused on fine tuning its imaging protocols and determining the most clinically-relevant set of biomarkers to include in its platform that can look for existential risks in an asymptomatic population. In 75 minutes or less, members are able to get a comprehensive picture of their health and receive a web-based dashboard that they can review from anywhere in the world with their chosen clinicians. The company, based in Redwood City, quietly opened its doors to a limited membership in late 2019 and plans to open additional locations this year.
“Q Bio makes true preventive medicine possible today,” said Vijay Pande, general partner, Andreessen Horowitz. “By measuring everything from blood to imaging and more in a longitudinal way, patients can have personalized baselines and physicians the data and power to understand, interpret and utilize this data to personalize care.”
As part of this new round of funding, Pande along with Vinod Khosla from Khosla Ventures will formally join Kaditz on the company’s Board of Directors. Clarissa Shen, who joined in 2019 as Q Bio Chief Operating Officer, will also join as a Board Observer.
About Q Bio
Founded in 2015 by serial entrepreneur Jeff Kaditz, Dr. Michael Snyder and Dr. Garry Choy, Q Bio gives you a deeper understanding of your body and how it’s changing, so you have more control over your health. Q Bio’s platform is a quantitative, clinically-relevant assessment of personal human health. We believe in making preventive health available to everyone so that treatable diseases no longer take lives.
Investors include Andreessen Horowitz, Khosla Ventures, Founders Fund, Beast Ventures, Thirty5 Venturers, Sea Lane Venturers and SciFi VC. For more information, visit q.bio.